Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)

NCT04964960 is registered in ClinicalTrials.gov with John L. Villano, MD, PhD as lead sponsor.

NCT NCT04964960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
John L. Villano, MD, PhD
Phase
Phase 2
Overall status
Terminated
Start date
May 19, 2022
Completion date
December 19, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, cancer, lung cancer, lung cancer metastatic